United States Patent 5,573,748: Scope, Claim Construction, Expiration, and Technetium-99m Patent Landscape

US 5,573,748 protects a prepackaged radiopharmaceutical kit for preparing a technetium-99m complex from a sulfur- or nitrogen-containing ligand, stannous reducing agent, and intermediate exchange ligand. The claims focus on the kit configuration and reagent combination, not on every technetium-99m compound or every method of using the resulting radiopharmaceutical.

The patent issued on November 12, 1996. Because the underlying application appears to fall under the pre-Uruguay Round Agreement Act patent-term rules, the nominal US term was 17 years from issuance, producing an expiration date of November 12, 2013, subject to any terminal disclaimer, patent-term adjustment, or other prosecution-specific modification. The patent is therefore no longer an enforceable US patent. [1]

What does US Patent 5,573,748 claim?

The independent claim covers a complete, preassembled kit containing four functional elements:

Required element	Claim requirement
Container	Must have sufficient volume to receive technetium-99m pertechnetate and provide the desired radioactivity level
Ligand	A ligand within the claimed sulfur- or nitrogen-containing structural genus
Stannous salt	A water-soluble stannous salt in an amount sufficient to induce reaction with technetium-99m pertechnetate
Intermediate exchange ligand	One of the listed exchange ligands, including acetate, glycine, citrate, gluconate, tartrate, malate, lactate, pyrophosphate, or glucoheptonate

The claim is drafted as a kit claim. It requires the reagents to be present in the container before addition of the technetium-99m pertechnetate solution. The claim does not require the kit to contain technetium-99m at the time of manufacture.

That distinction is commercially important. A kit manufacturer could supply a nonradioactive vial containing the ligand, stannous salt, and exchange ligand, while the radiopharmacy adds sodium pertechnetate immediately before administration.

How broad is claim 1 of US 5,573,748?

Claim 1 has a broad chemical genus but a narrower product configuration.

Chemical breadth

The ligand definition permits:

X as sulfur or nitrogen;
a hydrogen or oxidation-protecting group at Y1 when X is sulfur;
several substituents at R1, R2, and Z;
carboxylic acid, amide, sulfonic acid, sulfonamide, hydroxymethyl, methyl, ethyl, and related substituents.

For sulfur-containing embodiments, claim 1 reaches both unprotected and protected sulfur ligands. Claim 3 identifies specific sulfur-protecting groups:

acetyl;
benzoyl;
acetamidomethyl;
trifluoroacetyl;
carboxymethylcarbonyl;
hydroxymethylcarbonyl.

The claim therefore covers a family of thiol-containing technetium ligands rather than one single active ingredient.

Kit limitation

The chemical genus does not operate independently of the kit limitation. A potentially relevant product must contain the claimed ligand together with:

a water-soluble stannous salt;
a listed intermediate exchange ligand; and
a container suitable for accepting technetium-99m pertechnetate.

A composition containing only the ligand would not satisfy the literal language of claim 1. A finished technetium-99m complex made from the ligand also would not necessarily infringe unless the accused product is the claimed kit or falls within another enforceable claim or patent.

Functional language

The phrases "suitable amount" and "sufficient to induce the reaction" introduce functional limitations. They require the stannous salt and exchange ligand to be present in quantities capable of performing the claimed radiolabeling process. They do not appear to require a particular concentration, vial fill volume, activity level, or manufacturing method, unless those limitations are imposed by the specification or prosecution history.

What do claims 2 through 6 add?

Claim	Additional limitation	Practical effect
2	X is sulfur	Excludes the nitrogen-containing branch of claim 1
3	Specifies six sulfur-protecting groups	Narrows the protected-thiol alternatives
4	Y1 is benzoyl and Y is a carboxymethyl group	Covers a particular benzoyl-protected sulfur ligand arrangement
5	Y is one of three substituted amino-acid-type groups	Targets more specific ligand side chains
6	Lists the intermediate exchange ligand	Narrows the exchange ligand to a defined group of compounds

Claim 6 is particularly important for infringement analysis because it identifies the exchange-ligand alternatives expressly. A kit using an exchange ligand outside the listed group may avoid claim 6, but it could still fall within claim 1 if the exchange ligand is otherwise within the broader claim language. The supplied claim text should be checked against the issued patent to determine whether claim 1 itself contains the same closed or open list and whether claim 6 uses "comprising" or equivalent open-ended language.

What formulations are protected by US 5,573,748?

The patent protects a formulation architecture rather than a conventional tablet, capsule, injectable solution, or sustained-release dosage form.

The relevant formulation is a nonradioactive radiopharmaceutical kit containing:

the chelating ligand;
a reducing agent, ordinarily a stannous salt;
an intermediate exchange ligand;
a container suitable for later addition of pertechnetate.

The kit may be supplied as a dry powder, lyophilized cake, or other solid or reconstitutable presentation if the product satisfies the claim elements. The claim text does not expressly require lyophilization, a specific buffer, an antioxidant, a pH range, a stabilizer, a vial closure, or a particular stannous salt.

A formulation that adds excipients does not necessarily avoid infringement because the claim uses "comprising." Additional ingredients can be present unless they alter the claim construction or create a materially different product outside the claim.

Does the patent cover MAG3 or other technetium-99m compounds?

The claims are directed to a kit for producing a technetium-99m compound with the claimed general formula. The supplied claims do not identify a single commercial name such as technetium-99m mertiatide or technetium-99m MAG3.

The patent may read on particular mercaptoacetyl-based technetium agents if the ligand and resulting complex satisfy the structural definitions. That question requires a structure-by-structure comparison of:

the commercial ligand;
the protected or unprotected sulfur atom;
the Y, Y1, R1, R2, and Z substituents;
the resulting technetium coordination structure; and
the actual contents of the marketed kit.

A product cannot be classified solely by its clinical use as a renal imaging agent. Patent coverage depends on the ligand structure and the supplied kit components.

What was the patent’s likely commercial purpose?

The claim architecture addresses the practical chemistry of technetium-99m labeling. Pertechnetate is a high-valent technetium species that generally requires reduction before coordination with a ligand. The stannous salt performs the reduction function. The intermediate exchange ligand helps control or facilitate transfer of technetium from reduced pertechnetate to the target ligand.

The patent therefore targets manufacturing and radiopharmacy logistics:

stabilizing the ligand before labeling;
controlling sulfur oxidation;
improving kit reconstitution;
promoting technetium transfer;
allowing the user to add pertechnetate at the point of use; and
producing a radiopharmaceutical with a desired activity level.

The claimed combination is narrower than a broad claim to "a technetium-99m complex" but potentially more commercially relevant for kit manufacturers because it maps directly onto a sellable radiopharmaceutical vial.

When did US 5,573,748 lose exclusivity?

The patent’s nominal expiration date was November 12, 2013, assuming the standard 17-year term from issuance applicable to the relevant pre-1995 filing regime. [1] The patent is not a current US barrier to generic or alternative kit development.

The patent could have had earlier limitations from:

a terminal disclaimer;
disclaimer of claims;
reexamination;
a court judgment;
failure to pay a maintenance fee; or
claim cancellation during prosecution.

Those events would affect historical enforceability, but none would restore exclusivity after the stated nominal expiration date.

Patent-term extension

A patent covering a radiopharmaceutical kit could theoretically be evaluated for regulatory patent-term extension under 35 U.S.C. § 156. The supplied information does not establish that a patent-term extension was granted. The standard expiration analysis therefore uses the ordinary patent term. [2]

What was the Orange Book status?

The Orange Book lists approved drug products and certain patent and exclusivity information submitted by applicants. Patent listing is product- and NDA-specific. A patent covering a kit does not automatically appear in the Orange Book merely because it relates to a radiopharmaceutical. [3]

For this patent, the relevant regulatory issue would have been whether the NDA holder submitted US 5,573,748 as a patent claiming:

the approved drug substance;
the approved drug product;
a method of using the approved product; or
an approved formulation or kit.

The claims supplied are kit claims. They are not conventional method-of-use claims and do not, on their face, claim administration to a patient, renal imaging, or a diagnostic indication. Their Orange Book relevance would therefore depend on whether the approved product was legally characterized as the claimed kit and whether the NDA holder submitted the patent for listing.

After expiration, any historical Orange Book listing would no longer create a live patent exclusion.

Were Paragraph IV challenges relevant?

A Paragraph IV certification would have been relevant only if:

an NDA holder listed the patent in the Orange Book;
a generic applicant submitted an ANDA referencing the relevant approved product; and
the generic applicant asserted that the patent was invalid, unenforceable, or not infringed.

Because the claims are kit claims, the risk would have centered on whether the ANDA product contained the same ligand, stannous salt, exchange ligand, and container configuration.

Potential noninfringement positions could have included:

using a different ligand outside the claimed structural genus;
omitting the claimed intermediate exchange ligand;
using an exchange ligand not covered by the relevant claim;
supplying the components in separate containers rather than the claimed container;
using a non-stannous reducing system;
marketing a finished radiolabeled product rather than the claimed prepackaged kit.

Potential validity challenges could have focused on:

anticipation by earlier technetium kit patents;
obviousness based on known stannous reduction systems and exchange ligands;
indefiniteness of "suitable amount" or "desired level of radioactivity";
written-description support for the full ligand genus;
enablement across the large combination of substituent choices; and
claim construction of the Markush-style chemical definitions.

No current Paragraph IV risk arises from US 5,573,748 because the patent has expired.

Which companies would have been exposed to the patent?

The principal commercial exposure would have applied to companies supplying technetium-99m renal imaging kits using a ligand within the claimed genus. Relevant business categories include:

Business category	Exposure
Radiopharmaceutical manufacturers	High if supplying the complete claimed vial
Generic kit manufacturers	High before expiration if copying the claimed reagent combination
Hospital radiopharmacies	Generally lower, unless independently manufacturing or distributing kits
Nuclear pharmacies	Primarily users of the kit rather than commercial kit suppliers
Diagnostic imaging providers	Usually indirect exposure through procurement
Suppliers of individual ligands	Limited unless selling the complete claimed combination

The claims do not broadly capture every supplier of stannous chloride, every technetium-99m generator, or every renal imaging product. The relevant infringement unit is the packaged kit containing the required combination.

How strong was the patent estate?

Based on the supplied claims, US 5,573,748 was a focused but potentially useful kit patent.

Strengths

It claims a commercial product configuration rather than only a laboratory method.
It combines chemical and packaging limitations.
It includes a broad ligand genus in claim 1.
It expressly covers sulfur-protected ligand embodiments.
It identifies exchange ligands used in practical technetium-labeling chemistry.
It can capture kits with additional excipients because of the "comprising" format.

Weaknesses

The patent does not claim every technetium-99m complex.
The container limitation may create noninfringement opportunities.
A competitor could pursue a different ligand or exchange system.
Functional terms such as "suitable amount" can create construction disputes.
The patent’s term ended in 2013.
The claims do not establish protection for a particular clinical indication.
The supplied claim set does not show claims directed to manufacturing, use, purification, stability, or administration.

The patent was therefore most valuable as an early market-entry barrier for copied kit formulations. It was less capable of blocking chemically distinct technetium-99m radiopharmaceuticals.

What patent landscape surrounds technetium-99m kit technology?

The surrounding landscape generally divides into five patent groups:

Chelator and ligand patents
These cover sulfur, nitrogen, oxygen, or mixed-donor ligands used to bind reduced technetium.
Protected-thiol patents
These cover protection and deprotection strategies that prevent oxidation during storage.
Kit formulation patents
These cover stannous salts, buffers, antioxidants, exchange ligands, lyophilized presentations, and vial configurations.
Radiolabeling process patents
These cover reduction, ligand exchange, heating, reaction time, pH, purification, and generator-derived pertechnetate.
Clinical-use patents
These cover renal imaging, hepatobiliary imaging, myocardial perfusion, infection imaging, or other diagnostic uses.

US 5,573,748 sits primarily in the third category, with chemical subject matter overlapping the first and second categories. It does not appear from the supplied claims to be a broad platform patent covering all technetium-99m radiopharmaceuticals.

What generic entry risks existed before expiration?

Before 2013, a competing kit would have faced the following risk profile:

Development path	Pre-expiration risk
Exact copy of ligand and excipient system	High
Same ligand but different exchange ligand	Claim-dependent
Same ligand supplied in separate containers	Potentially lower
Different technetium chelator	Potentially low
Finished technetium-99m product made outside the kit format	Dependent on other claims
Hospital compounding for internal use	Fact-specific
New indication using the same kit	Not necessarily sufficient to avoid kit claims

The most credible design-around strategy would have been to change the ligand structure or replace the exchange-ligand system while preserving acceptable radiolabeling performance. A packaging change alone could have been less reliable if the product still met the container and "prepackaged kit" limitations.

What litigation and settlement issues should be reviewed?

A complete historical enforcement review should focus on:

district court cases naming the patent number;
International Trade Commission investigations involving technetium kits;
ANDA litigation concerning the relevant NDA;
reexamination or post-grant proceedings;
terminal disclaimers and assignment records;
settlement agreements involving generic radiopharmaceutical manufacturers; and
Orange Book delisting or patent-listing disputes.

The claim text alone does not establish that US 5,573,748 was litigated, challenged through Paragraph IV, or included in a settlement. The patent’s expiration also means that any historical dispute no longer creates a forward-looking US launch block.

Key Takeaways

US 5,573,748 is a kit patent for preparing technetium-99m complexes from defined ligands.
Claim 1 requires a ligand, water-soluble stannous salt, intermediate exchange ligand, and suitable container.
Claims 2 through 6 narrow the invention toward sulfur ligands, protected sulfur groups, specific side chains, and listed exchange ligands.
The patent does not broadly claim every technetium-99m complex or every renal imaging product.
Its nominal US expiration date was November 12, 2013.
There is no current US patent exclusivity based on this patent.
Historical Paragraph IV and Orange Book relevance depended on the specific approved product and NDA listing.
The strongest historical infringement theory involved a commercial kit copying the ligand and reagent combination.
The strongest design-around routes involved changing the ligand, exchange ligand, reducing system, or kit configuration.
Biosimilar analysis is not applicable because the claimed subject matter is a small-molecule radiopharmaceutical kit, not a biologic.

FAQs

Does US 5,573,748 claim technetium-99m itself?

No. The claims require a prepackaged kit used to prepare a technetium-99m compound. They do not claim the radionuclide as a standalone substance.

Can a kit avoid the patent by using a different stannous salt?

Not necessarily. Claim 1 requires a water-soluble stannous salt but does not appear to limit the claim to one named stannous compound. A different water-soluble stannous salt could remain within the claim.

Does changing the vial size avoid infringement?

Not necessarily. The claim requires sufficient container volume for accepting pertechnetate and providing the desired radioactivity level. A different vial size could still satisfy that limitation.

Are technetium-99m products subject to biosimilar competition?

No. Biosimilar pathways apply to biological products. Technetium-99m radiopharmaceutical kits are regulated as drug products and are evaluated through applicable drug approval and generic pathways.

Is a new renal imaging indication blocked by this patent?

No current block exists because the patent expired in 2013. Historically, the claims supplied were kit claims rather than claims directed to a renal imaging indication.

References

United States Patent No. 5,573,748. (1996). United States Patent and Trademark Office.
United States Code, 35 U.S.C. § 156. Patent term extension.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	60714	⤷ Start Trial
Australia	4327085	⤷ Start Trial
Australia	581003	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,573,748

Summary for Patent: 5,573,748